Back to top
more

CRISPR Therapeutics (CRSP)

(Real Time Quote from BATS)

$58.87 USD

58.87
2,494,991

+3.22 (5.79%)

Updated May 14, 2024 09:33 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Nov 8, 2023

by Zacks Equity Research

Companies in The News Are: EMR,DHI,CRSP,ATSG

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

by Zacks Equity Research

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View

by Zacks Equity Research

Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.

Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Wall Street Analysts See a 108.46% Upside in CRISPR Therapeutics AG (CRSP): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 108.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Vertex (VRTX) is likely to outperform third-quarter 2023 estimates, driven by the increased international sales of its lead drug, Trikafta/Kaftrio.

CRISPR Therapeutics AG (CRSP) Stock Moves -0.18%: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reachead $39.11 at the closing of the latest trading day, reflecting a -0.18% change compared to its last close.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.

Intellia (NTLA) Focuses on Developing Gene-Editing Therapies

by Zacks Equity Research

Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.

BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank

by Zacks Equity Research

BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%. Shares fall.

Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance

by Zacks Equity Research

Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.

CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $44.81, indicating a +1.13% shift from the previous trading day.

Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation

by Zacks Equity Research

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.

Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.

BioCardia (BCDA) Up on Plans for Second Heart Failure Study

by Zacks Equity Research

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.

BEAM Focuses on Developing Gene Drug for Growth

by Zacks Equity Research

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $43.06, indicating a +0.14% shift from the previous trading day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $45.39, moving -0.77% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Stock Moves -1.07%: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.06, marking a -1.07% move from the previous day.